Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
Location status: Recruiting
NCT Number: NCT06562582
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
Gothenburg, 41345, Sweden
Location status: Recruiting
Left ventricular (LV) remodeling after ST-elevation myocardial infarction (STEMI) is associated with poor outcomes, but the mechanisms underlying adverse LV remodeling are poorly understood. It is also poorly understood how current guideline-recommended treatments affect early LV remodeling. This low interventional clinical trial will compare the effects of early versus late initiation of the three pharmacotherapies on early LV remodeling and cardiometabolic profiles.
Trial objective:
The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium/glucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI).
Primary endpoint:
Global longitudinal strain (GLS, %) at day 7±24 hours after PCI, adjusted for baseline (day 0) GLS.
Trial design:
This prospective, 2x2x2 factorial, randomized, controlled, open-label, low intervention clinical trial will enroll subjects with STEMI who undergo primary percutaneous coronary intervention (PCI) within 6 hours of symptom onset.
Trial population:
Patients over the age of 18 with STEMI who undergo primary PCI
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Timing of drug intervention after PCI
Other names: Betablocker
Timing of drug intervention after PCI
Other names: ACE inhibitor
Timing of drug intervention after PCI
Other names: SGLT2 inhibitor
Time frame: day 7±24 hours
GLS adjusted for baseline.
Time frame: day 7±24 hours
LVEF adjusted for baseline
Time frame: day 7±24 hours
NT-proBNP adjusted for baseline
Time frame: Day 30
Area under the curve
Time frame: Day 30
Area under the curve
Time frame: Day 30
MI size assessed by CMRI (sub-study)
Contact information is provided by the study sponsor or research team.
Björn Redfors, Professor
CONTACT
Margareta Scharin Täng, PhD
CONTACT
Vastra Gotaland Region
Other Gov
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
Acronym: STAMI-BAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06927739
Acute Coronary Syndrome, Acute Coronary Syndromes
Los Angeles, California, United States
View Trial DetailsNCT06662890
Cardiovascular Diseases, Heart Diseases
Clydebank, Dunbartonshire, United Kingdom
View Trial DetailsNCT06697418
Behavior, Cardiovascular Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01033617
Cardiovascular Diseases, Heart Diseases
Montreal, Quebec, Canada
View Trial Details